openPR Logo
Press release

Handheld Devices for Injecting Viscous Drugs Becoming a Defined Market

09-05-2018 09:04 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The high value, proliferation and properties of biological drugs are creating opportunities and challenges for device developers. In particular, sector participants are attempting to address the issue of high viscosity, and in the process are extending the design envelope for needle-based injectors. These companies are attempting to accommodate a range of viscous drugs that extend from 20 to over 1000 cP.
The five categories of handheld injection devices that can reliably administer high viscosity drugs includes legacy devices, modified designs, non-glass injectors, NFI and novel devices based upon pressurized gas and mechanical assist designs. As a group the current crop of devices is capable of meeting the viscosity challenge in a wide range of use cases.
Injection devices designed to deliver high viscosity drugs employ a number of methods for moving the drug from the primary container, through the cannula or needle, and into the patient. Most of the devices utilize a piston or piston-type method to deliver the drug, although liquified, pressurized gas and mechanically assisted devices have been introduced.
As currently formulated, biological drugs require dosage volumes well in excess of the upper range for subcutaneous delivery. Because the current class of biologicals has been developed for long-term self-administration, they represent the first group of injectables that have been designed with the end user in mind. These drugs are the first beyond insulin and vaccines to limit packaging in vials in favor of prefilled syringes and specialty injection devices. The price points for recombinant protein drugs allow developers to view the higher cost of customized branded delivery devices as an investment in patient compliance and satisfaction.
Highly concentrated systems present major concerns with respect to syringeability and injectability, especially as these products are typically stored refrigerated and temperature causes viscosity to increase significantly. Devices designed for use in injecting drugs with higher viscosities require features that reduce the amount of resistance of the drug to flow through the injection needle. These methods can be formulaic, resulting in a reduction of the shear force produced in Newtonian fluids, or they may be the result of materials selection and refinement. Some of the work in this area revolves are such injection specific parameters as plunger-stopper breakloose force, maximum force, and dynamic glide force.
As the trend toward self-administration continues, the need for careful consideration of primary container design and interaction with biologics, devices, and the patient becomes more critical. Regulatory scrutiny in this space is likely to continue to increase, requiring a more proactive approach on the part of pharmaceutical/biologic companies to address these questions.
Because a significant number of injectable drugs are being formulated or re-formulated for self-administration, it has become essential for drug developers and the injection device design partners to understand user preferences and to define usability features as they pertain to specific treatment groups. The critical nature of this requirement is further underscored by the design trend in specialty prefilled devices to incorporate a unique look-and-feel to devices in order to achieve product differentiation in the direct-to-consumer marketplace.
The biological drug sector and the challenge of administering biologicals are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Handheld Devices for Injecting High Viscosity Drugs analyzes injectable devices capable of administering viscous drugs. The report includes analysis of competitive factors, therapeutic class product positioning, supply chain factors, supplier segment coverage strategies, and the product activities of sector participants.

More information is available at http://www.greystoneassociates.org



Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Communication Director
Greystone Research Associates
98 Route 101A
Amherst, NH 03031
Voice: 603-595-4340
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Handheld Devices for Injecting Viscous Drugs Becoming a Defined Market here

News-ID: 1220255 • Views: 176

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for Amherst

Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge
(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these
New Aircraft Designs Creating Opportunities for High Performance Aerospace Coati …
(Amherst, NH) – As aerospace manufacturers and their engineering teams push the design envelope to create aircraft with better fuel efficiency and lower maintenance requirements, they are relying increasingly on engineered materials for a growing list of structural and non-structural elements and components. This trend is changing the way aircraft are developed, produced and maintained. It’s also presenting opportunities for specialty materials suppliers with products that can improve production
Evolution in Markets for Radiation Curable Coatings Creating Risks and Opportuni …
(Amherst, NH) – Recent advances in materials and equipment are creating new demand for radiation curable coatings in a number of industrial applications. This new demand is occurring as several technology advances are being brought into the marketplace. By removing some of the key limitations of radcure coatings, these advances are enabling radcure coatings to meet unique application requirements, opening up a number of new opportunities. Technical advances that are having
Drug Delivery Coatings Creating Opportunities for Developers and Practitioners
(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a
Adros Energy Expands Clean Energy Business with Energy Audit Services and opens …
Adros Energy; a leading green energy company in New England, announced today that they are opening a new headquarters in Amherst, NH after a successful 1st year of operation in the renewable energy market. The company was founded in January of 2009 and has found success during the incubation period of the company. The infrastructure building of the company in 2009 includes: • Revenue generation from its solar PV,
Esensors Adds New Websensor Features
July 22, 2008 – Amherst, NY – EM01B Websensor is an environmental sensor that provides accurate measurement of temperature, relative humidity and light over a network. This month, Esensors adds some new features to EM01B Websensor. The free Websensor Data Logger now enables users to easily export the data to other software tools for analysis. This allows the flexibility to generate custom data views and make data collection more